OncoTargets and Therapy (Sep 2020)

Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization

  • Cao S,
  • Zhu S,
  • Yin W,
  • Xu H,
  • Wu J,
  • Wang Q

Journal volume & issue
Vol. Volume 13
pp. 9407 – 9417

Abstract

Read online

Shengya Cao,1 Shuo Zhu,2 Wei Yin,1 Heng Xu,3 Jianzhong Wu,4 Qiang Wang1,5 1Department of Clinical laboratory, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, People’s Republic of China; 2Department of Hepatobiliary Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, People’s Republic of China; 3Laboratory of Pharmaceutical Chemistry, Jiangsu Province Institute of Materia Medica, Nanjing Tech University, Nanjing, Jiangsu 210000, People’s Republic of China; 4Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210000, People’s Republic of China; 5Department of Radiotherapy, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, People’s Republic of ChinaCorrespondence: Jianzhong WuResearch Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, No. 7 Building, 42 BaiZiTing Road, Nanjing, Jiangsu 210000, People’s Republic of ChinaEmail [email protected] WangDepartment of Radiotherapy, Xuzhou Cancer Hospital, No. 131, Huancheng Road, Xuzhou, Jiangsu 221005, People’s Republic of ChinaEmail [email protected]: The aim of this study was to estimate the relevance of the epidermal growth factor receptor (EGFR) between serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9) in primary hepatocellular carcinoma (HCC) patients with transarterial chemoembolization (TACE).Methods: The pre-treatment and post-treatment concentrations of the serum VEGF and MMP‑9 were detected with Luminex assay in 80 EGFR-negative patients and 59 EGFR-positive patients who received TACE therapy with different chemotherapeutic drugs.Results: The serum concentration of MMP-9 in the EGFR-positive patients with primary HCC was significantly higher than that in the EGFR-negative patients (P < 0.05). In EGFR-positive patients with primary HCC, differences in stage, metastasis, and differentiation were significant (P < 0.05). Serum VEGF level significantly decreased at the second course of treatment in the EGFR-negative patients from the P group (P < 0.05), while serum MMP-9 level significantly decreased at the second course of treatment in the EGFR-negative patients from the E group (P < 0.05). Serum VEGF level in the EGFR-positive patients among three groups slightly decreased at the first, second and third courses of treatments; however, the differences were not significant (P > 0.05). Serum MMP-9 level in the EGFR-positive patients among three groups showed mild decrease at the first and second courses of treatments; however, the decreases at the third course of treatment were significant (P < 0.05).Conclusion: Serum VEGF and MMP-9 are potential biomarkers for the treatment monitoring of EGFR-positive and -negative patients after TACE therapy with different chemotherapeutic drugs.Keywords: hepatocellular carcinoma, transarterial chemoembolization, EGFR, VEGF, MMP-9

Keywords